Magnetic Resonance Imaging of Myocardial Infarction Using a Manganese-Based Contrast Agent (EVP 1001-1): Preliminary Results in a Dog Model.
Storey, Pippa PhD 1,2,*; Chen, Qun PhD 3; Li, Wei MD 1,2; Seoane, Peter R. PhD 4; Harnish, Phillip P. PhD 4; Fogelson, Laura CVT 1; Harris, Kathleen R. BA 5; Prasad, Pottumarthi V. PhD 1,2
[Article] Journal of Magnetic Resonance Imaging. 23(2):228-234, February 2006.

(Format: HTML, PDF)

Purpose: To investigate the MRI characteristics of an intracellular manganese-based contrast agent, EVP 1001-1 (Eagle Vision Pharmaceutical Corp.), in a canine model of myocardial infarction.

Materials and Methods: Three dogs were imaged 14-37 days following permanent ligation of the left anterior descending coronary artery (LAD). Measurements of the longitudinal relaxation rate R1 were made prior to EVP 1001-1 administration (20 [mu]mol/kg i.v.) and for one hour thereafter. Triphenyl tetrazolium chloride (TTC) staining was used to document infarction.

Results: In normal myocardium, EVP 1001-1 produced a substantial increase in the longitudinal relaxation rate, which remained fairly constant over the postcontrast imaging period ([DELTA]R1 = 1.47 /- 0.58 sec-1 (mean /- SD) at 35 minutes, P < 0.05). In the infarct, the response to EVP 1001-1 was small or negligible ([DELTA]R1 = 0.27 /- 0.28 sec-1). This resulted in a significant postcontrast difference in relaxation rate between normal and infarcted tissue (R1(normal) - R1(infarct) = 1.08 /- 0.26 sec-1, P < 0.05). The infarct remained clearly delineated in all animals throughout the steady-state imaging period, and qualitatively matched TTC results.

Conclusion: The persistent enhancement pattern revealed by MRI following EVP 1001-1 administration may be beneficial for identifying and characterizing myocardial infarction. J. Magn. Reson. Imaging 2006. (C) 2006 Wiley-Liss, Inc.

Copyright (C) 2006 John Wiley & Sons, Inc.